Companies › Continuity Biosciences
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ACT-IOP-003 Implantable iontophoresis device for direct pancreatic delivery of gemcitabine | – | Phase 1 | Pancreatic Adenocarcinoma Non-resectable | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07481383 | ACT-IOP-003 | Phase 1 | Pancreatic Adenocarcinoma Non-resectable | Oncology | Aug 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.